About the Webinar
Advances in genome sequencing and related technology have led to unprecedented pace at which we can identify genomic and epigenetic changes associated with human diseases. For this purpose, genome editing tools adapted from CRISPR-Cas system can be employed for modifying genomic sequences at massive scale. In this webinar we will discuss:
- How genome engineering technology based on the CRISPR system can be deployed as versatile discovery and therapeutics tool.
- The power and precision of novel technology development and its potential ex vivo and in vivo applications.
- The emerging trend on how genomics analysis could be integrated to transform our ability to understand and treat human diseases, particularly complex diseases such as cancer via tumor immunology approaches.
About the Presenter
Dr. Le Cong obtained a B.S. with highest honor from Tsinghua University, and a Ph.D. from Harvard University. He is currently a Postdoctoral Associate at the Broad Institute and MIT. He completed his doctoral work in Dr. Feng Zhang’s lab at the Broad Institute, where he published a seminal study demonstrating the harnessing of CRISPR-Cas9 for genome editing, which became the most highly cited paper in the CRISPR field. He subsequently published multiple high-impact studies further advancing the CRISPR-Cas9 technology including engineering CRISPR-Cas9 for gene therapy applications. Dr. Cong received multiple awards for his pioneering work in gene editing including the Howard Hughes Medical Institute (HHMI) International Student Research Fellowship and the Cancer Research Institute (CRI) Irvington Postdoctoral Fellowship Award.